PON1 and COVID-19: The new prognostic biomarkers associated with COVID-19 reported here not only serve in conjunction with diagnostic RNA, antigen, and antibody detection tests to complement other previously identified biomarkers such as IL-6, but also provide the possibility of using highly abundant serum proteins for prognosis of disease severity (e.g., CBP2, up to 0.1 mg/ml), asymptomatic carriers (e.g., PZP, up to 350 ng/ml), or disease recovery (e.g., PON1, up to 160 ng/ml).